In an interview to CNBC-TV18, Piyush Rathi, Director & CMO of Advanced Enzyme Technologies spoke about the results and his outlook for the company.
CL Rathi, MD of Advanced Enzyme Technologies sees huge future for the company in nutrition growth along with animal nutrition.
In an interview to CNBC-TV18, CL Rathi, MD of Advanced Enzyme Technologies spoke about the results and his outlook for the company.
CL Rathi, Managing Director and Chief Executive of Advanced Enzyme, said the acquisition will be EPS-accretive for FY17 and is likely to have a positive impact for FY18.
Do not need any money for capex over next two-three years, says CL Rathi, MD of Advanced Enzyme Technologies.
The enzymes market in India is small and the company wants to expand in Americas, West Asia and far East, according to CL Rathi, Managing Director of Advanced Enzyme Technologies.
Speaking to CNBC-TV18, CL Rathi, MD of Advanced Enzymes (AETL) said its misguiding to compare its business with Novozymes. While AETL gets 75 percent of its business from nutrition segment, Novozymes has higher exposure to industrials where input costs are causing pressures.